Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiosurgery | 61 | 2020 | 356 | 7.750 |
Why?
|
Brain Neoplasms | 69 | 2021 | 638 | 6.980 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2020 | 370 | 2.260 |
Why?
|
Glioma | 15 | 2021 | 136 | 1.890 |
Why?
|
Meningioma | 10 | 2020 | 57 | 1.480 |
Why?
|
Trigeminal Neuralgia | 9 | 2019 | 33 | 1.330 |
Why?
|
Meningeal Neoplasms | 8 | 2017 | 49 | 1.270 |
Why?
|
Middle Aged | 86 | 2020 | 11827 | 1.220 |
Why?
|
Retrospective Studies | 49 | 2020 | 3523 | 1.210 |
Why?
|
Laser Therapy | 6 | 2020 | 55 | 1.200 |
Why?
|
Treatment Outcome | 45 | 2020 | 3313 | 1.190 |
Why?
|
Glioblastoma | 12 | 2020 | 156 | 1.120 |
Why?
|
Salvage Therapy | 16 | 2020 | 134 | 1.090 |
Why?
|
Adult | 67 | 2020 | 9346 | 1.060 |
Why?
|
Aged | 69 | 2020 | 10318 | 1.050 |
Why?
|
Female | 91 | 2020 | 19969 | 0.990 |
Why?
|
Humans | 112 | 2020 | 32004 | 0.980 |
Why?
|
Male | 84 | 2020 | 19169 | 0.960 |
Why?
|
Parkinson Disease | 9 | 2020 | 82 | 0.910 |
Why?
|
Intracranial Arteriovenous Malformations | 3 | 2012 | 21 | 0.840 |
Why?
|
Deep Brain Stimulation | 8 | 2020 | 49 | 0.830 |
Why?
|
Antineoplastic Agents, Alkylating | 5 | 2018 | 40 | 0.820 |
Why?
|
Magnetic Resonance Imaging | 18 | 2018 | 1328 | 0.810 |
Why?
|
Negative-Pressure Wound Therapy | 4 | 2016 | 36 | 0.760 |
Why?
|
Cerebellar Neoplasms | 2 | 2019 | 11 | 0.750 |
Why?
|
Drug Delivery Systems | 5 | 2021 | 104 | 0.750 |
Why?
|
Postoperative Complications | 6 | 2019 | 784 | 0.750 |
Why?
|
Follow-Up Studies | 26 | 2020 | 2277 | 0.740 |
Why?
|
Antineoplastic Agents | 9 | 2020 | 608 | 0.740 |
Why?
|
Aged, 80 and over | 33 | 2020 | 3995 | 0.700 |
Why?
|
Cranial Irradiation | 9 | 2020 | 93 | 0.700 |
Why?
|
Brain | 6 | 2015 | 951 | 0.700 |
Why?
|
Hemangioblastoma | 1 | 2019 | 4 | 0.660 |
Why?
|
von Hippel-Lindau Disease | 1 | 2019 | 5 | 0.660 |
Why?
|
Neurosurgical Procedures | 4 | 2015 | 99 | 0.580 |
Why?
|
Carmustine | 3 | 2015 | 8 | 0.570 |
Why?
|
Combined Modality Therapy | 11 | 2018 | 564 | 0.570 |
Why?
|
Dura Mater | 2 | 2012 | 14 | 0.510 |
Why?
|
Stereotaxic Techniques | 5 | 2020 | 23 | 0.500 |
Why?
|
Convection | 3 | 2021 | 8 | 0.490 |
Why?
|
Treatment Failure | 12 | 2020 | 163 | 0.470 |
Why?
|
Young Adult | 17 | 2020 | 2638 | 0.460 |
Why?
|
Corpus Striatum | 3 | 2020 | 60 | 0.450 |
Why?
|
Radiotherapy | 6 | 2018 | 82 | 0.440 |
Why?
|
Disease-Free Survival | 10 | 2020 | 319 | 0.420 |
Why?
|
Craniocerebral Trauma | 1 | 2012 | 56 | 0.410 |
Why?
|
Subthalamic Nucleus | 5 | 2020 | 13 | 0.400 |
Why?
|
Facial Pain | 5 | 2014 | 21 | 0.390 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2017 | 77 | 0.380 |
Why?
|
Genetic Vectors | 2 | 2010 | 120 | 0.370 |
Why?
|
Survival Analysis | 14 | 2020 | 487 | 0.370 |
Why?
|
Melanoma | 6 | 2019 | 164 | 0.360 |
Why?
|
Multiple Sclerosis | 3 | 2019 | 59 | 0.360 |
Why?
|
Survival Rate | 11 | 2020 | 885 | 0.350 |
Why?
|
Serotonin | 2 | 2020 | 37 | 0.340 |
Why?
|
Anticonvulsants | 1 | 2009 | 65 | 0.330 |
Why?
|
Radiation Injuries | 5 | 2018 | 75 | 0.330 |
Why?
|
Lung Neoplasms | 5 | 2017 | 410 | 0.320 |
Why?
|
Radiotherapy Dosage | 9 | 2017 | 101 | 0.300 |
Why?
|
Nomograms | 4 | 2017 | 32 | 0.300 |
Why?
|
Neoplasms | 4 | 2020 | 724 | 0.290 |
Why?
|
Adolescent | 11 | 2020 | 3540 | 0.290 |
Why?
|
Dopamine | 3 | 2020 | 232 | 0.290 |
Why?
|
Decision Making | 2 | 2020 | 195 | 0.290 |
Why?
|
Prognosis | 10 | 2020 | 1503 | 0.280 |
Why?
|
Hypothalamo-Hypophyseal System | 4 | 2008 | 31 | 0.280 |
Why?
|
Brain Edema | 4 | 2014 | 15 | 0.270 |
Why?
|
Surgery, Computer-Assisted | 4 | 2017 | 53 | 0.270 |
Why?
|
Child | 8 | 2020 | 2436 | 0.260 |
Why?
|
Thalamus | 2 | 2015 | 33 | 0.240 |
Why?
|
Glutamate Decarboxylase | 2 | 2017 | 17 | 0.240 |
Why?
|
Postural Balance | 1 | 2016 | 181 | 0.230 |
Why?
|
Benzenesulfonates | 1 | 2003 | 3 | 0.230 |
Why?
|
Iodine Radioisotopes | 1 | 2003 | 16 | 0.230 |
Why?
|
Brachytherapy | 1 | 2003 | 24 | 0.220 |
Why?
|
Pesticides | 1 | 2016 | 199 | 0.220 |
Why?
|
Catheterization | 1 | 2003 | 58 | 0.220 |
Why?
|
Occupational Exposure | 1 | 2016 | 232 | 0.220 |
Why?
|
Central Nervous System Neoplasms | 2 | 2014 | 29 | 0.210 |
Why?
|
Transients and Migrants | 1 | 2016 | 290 | 0.210 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 244 | 0.210 |
Why?
|
Neurons | 3 | 2015 | 410 | 0.210 |
Why?
|
Adenocarcinoma | 2 | 2017 | 312 | 0.210 |
Why?
|
Brain Injuries | 2 | 2014 | 93 | 0.210 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2012 | 28 | 0.210 |
Why?
|
Cerebral Angiography | 2 | 2012 | 60 | 0.200 |
Why?
|
Breast Neoplasms | 4 | 2017 | 768 | 0.200 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2013 | 154 | 0.190 |
Why?
|
Astrocytoma | 3 | 2018 | 29 | 0.190 |
Why?
|
Receptor, EphA2 | 1 | 2021 | 13 | 0.190 |
Why?
|
Radiation Dosage | 5 | 2020 | 84 | 0.180 |
Why?
|
Sulfones | 1 | 2020 | 21 | 0.180 |
Why?
|
Genomics | 2 | 2018 | 85 | 0.180 |
Why?
|
Indans | 1 | 2020 | 31 | 0.180 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 46 | 0.180 |
Why?
|
Registries | 2 | 2020 | 298 | 0.180 |
Why?
|
Arnold-Chiari Malformation | 2 | 2010 | 8 | 0.180 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 221 | 0.180 |
Why?
|
Brain Diseases | 1 | 2020 | 38 | 0.170 |
Why?
|
Craniotomy | 3 | 2017 | 46 | 0.170 |
Why?
|
Carcinoma | 1 | 2020 | 92 | 0.170 |
Why?
|
Hydrocortisone | 4 | 2008 | 57 | 0.170 |
Why?
|
Visual Perception | 1 | 2020 | 116 | 0.170 |
Why?
|
Hispanic Americans | 1 | 2016 | 940 | 0.170 |
Why?
|
Trigeminal Nerve | 2 | 2010 | 5 | 0.170 |
Why?
|
Pain Measurement | 4 | 2014 | 351 | 0.160 |
Why?
|
Movement Disorders | 2 | 2010 | 26 | 0.160 |
Why?
|
Reward | 2 | 2018 | 64 | 0.160 |
Why?
|
Prospective Studies | 7 | 2019 | 2280 | 0.160 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 99 | 0.160 |
Why?
|
Feedback, Psychological | 1 | 2018 | 6 | 0.150 |
Why?
|
Multivariate Analysis | 6 | 2018 | 687 | 0.150 |
Why?
|
Pituitary Gland | 2 | 2008 | 9 | 0.150 |
Why?
|
Disease Management | 2 | 2017 | 126 | 0.150 |
Why?
|
Cohort Studies | 5 | 2019 | 1821 | 0.150 |
Why?
|
Glomus Jugulare Tumor | 1 | 2017 | 4 | 0.150 |
Why?
|
Basal Ganglia | 2 | 2014 | 15 | 0.150 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 99 | 0.140 |
Why?
|
Brain Death | 2 | 2017 | 27 | 0.140 |
Why?
|
Nervous System Neoplasms | 1 | 2017 | 8 | 0.140 |
Why?
|
Medicare | 1 | 2018 | 207 | 0.140 |
Why?
|
Weight Gain | 2 | 2015 | 117 | 0.140 |
Why?
|
Time Factors | 7 | 2017 | 2152 | 0.140 |
Why?
|
Signal Transduction | 1 | 2020 | 682 | 0.140 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2017 | 33 | 0.140 |
Why?
|
Catheters, Indwelling | 2 | 2009 | 43 | 0.140 |
Why?
|
Immunotherapy | 1 | 2016 | 81 | 0.140 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 132 | 0.130 |
Why?
|
Spinal Cord Injuries | 1 | 2016 | 39 | 0.130 |
Why?
|
Animals | 11 | 2021 | 7542 | 0.130 |
Why?
|
Tremor | 1 | 2015 | 11 | 0.130 |
Why?
|
Gene Transfer Techniques | 2 | 2017 | 63 | 0.130 |
Why?
|
Risk Factors | 7 | 2019 | 3872 | 0.130 |
Why?
|
Retreatment | 3 | 2016 | 41 | 0.130 |
Why?
|
Drug Implants | 1 | 2015 | 9 | 0.130 |
Why?
|
Ganglioglioma | 1 | 2015 | 6 | 0.130 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2018 | 192 | 0.130 |
Why?
|
Hypesthesia | 2 | 2015 | 9 | 0.130 |
Why?
|
Central Nervous System Diseases | 1 | 2015 | 13 | 0.130 |
Why?
|
Neurofibromatosis 2 | 1 | 2015 | 5 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 3 | 2003 | 105 | 0.120 |
Why?
|
Carcinoma, Renal Cell | 2 | 2017 | 114 | 0.120 |
Why?
|
Proportional Hazards Models | 5 | 2015 | 756 | 0.120 |
Why?
|
Choice Behavior | 1 | 2015 | 87 | 0.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2014 | 34 | 0.120 |
Why?
|
Meningeal Carcinomatosis | 1 | 2014 | 7 | 0.120 |
Why?
|
Brain Stem Neoplasms | 1 | 2014 | 4 | 0.120 |
Why?
|
Incidence | 4 | 2020 | 1198 | 0.120 |
Why?
|
Sheep | 4 | 2008 | 233 | 0.120 |
Why?
|
Kidney Neoplasms | 2 | 2017 | 201 | 0.120 |
Why?
|
Exotoxins | 2 | 2003 | 13 | 0.110 |
Why?
|
Diphtheria Toxin | 2 | 2003 | 26 | 0.110 |
Why?
|
Epidermal Growth Factor | 2 | 2003 | 27 | 0.110 |
Why?
|
Interleukin-13 | 2 | 2003 | 28 | 0.110 |
Why?
|
Vein of Galen Malformations | 1 | 2013 | 4 | 0.110 |
Why?
|
Carcinoma, Small Cell | 1 | 2013 | 25 | 0.110 |
Why?
|
Cerebral Veins | 1 | 2013 | 12 | 0.110 |
Why?
|
Smoking | 1 | 2017 | 496 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 920 | 0.110 |
Why?
|
Tumor Burden | 4 | 2014 | 60 | 0.110 |
Why?
|
Influenza Vaccines | 1 | 2014 | 78 | 0.110 |
Why?
|
Cerebral Cortex | 1 | 2014 | 126 | 0.110 |
Why?
|
Skull Base Neoplasms | 1 | 2012 | 4 | 0.110 |
Why?
|
Dose-Response Relationship, Radiation | 4 | 2015 | 81 | 0.110 |
Why?
|
Spin Labels | 1 | 2012 | 24 | 0.110 |
Why?
|
Fatal Outcome | 1 | 2012 | 83 | 0.110 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2012 | 3 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2012 | 13 | 0.110 |
Why?
|
Carcinoma, Basal Cell | 1 | 2012 | 26 | 0.100 |
Why?
|
Scalp | 1 | 2012 | 38 | 0.100 |
Why?
|
Skull | 1 | 2012 | 48 | 0.100 |
Why?
|
Neurilemmoma | 1 | 2012 | 16 | 0.100 |
Why?
|
Nitrogen Mustard Compounds | 1 | 2012 | 4 | 0.100 |
Why?
|
Neoplasm Staging | 3 | 2015 | 456 | 0.100 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2012 | 17 | 0.100 |
Why?
|
Arginine Vasopressin | 2 | 2008 | 3 | 0.100 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2012 | 22 | 0.100 |
Why?
|
Procarbazine | 1 | 2011 | 5 | 0.100 |
Why?
|
Resuscitation | 1 | 2012 | 65 | 0.100 |
Why?
|
Collagen Diseases | 1 | 2011 | 5 | 0.100 |
Why?
|
Angiogenesis Inhibitors | 1 | 2011 | 36 | 0.100 |
Why?
|
Thalidomide | 1 | 2011 | 31 | 0.100 |
Why?
|
Hyperthermia, Induced | 1 | 2014 | 246 | 0.100 |
Why?
|
Double-Blind Method | 3 | 2020 | 525 | 0.090 |
Why?
|
Disease Progression | 3 | 2018 | 593 | 0.090 |
Why?
|
Viruses | 1 | 2010 | 3 | 0.090 |
Why?
|
Medulloblastoma | 1 | 2010 | 7 | 0.090 |
Why?
|
Algorithms | 1 | 2014 | 492 | 0.090 |
Why?
|
Vascular Diseases | 1 | 2011 | 66 | 0.090 |
Why?
|
Blood-Brain Barrier | 1 | 2010 | 48 | 0.090 |
Why?
|
Radiation Oncology | 1 | 2010 | 10 | 0.090 |
Why?
|
Posture | 1 | 2010 | 54 | 0.090 |
Why?
|
Lymphoma | 1 | 2010 | 35 | 0.090 |
Why?
|
Deglutition Disorders | 1 | 2010 | 51 | 0.090 |
Why?
|
Fetus | 3 | 2008 | 86 | 0.090 |
Why?
|
Age Factors | 1 | 2013 | 1189 | 0.090 |
Why?
|
Cognition Disorders | 1 | 2013 | 385 | 0.080 |
Why?
|
Case-Control Studies | 2 | 2016 | 894 | 0.080 |
Why?
|
Cell Line, Tumor | 3 | 2020 | 726 | 0.080 |
Why?
|
North Carolina | 3 | 2016 | 1514 | 0.080 |
Why?
|
Cell Proliferation | 3 | 2020 | 604 | 0.080 |
Why?
|
Neurofibromatoses | 1 | 2008 | 2 | 0.080 |
Why?
|
Recurrence | 3 | 2015 | 265 | 0.080 |
Why?
|
Mice, Nude | 2 | 2020 | 291 | 0.080 |
Why?
|
Ablation Techniques | 2 | 2018 | 26 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 510 | 0.080 |
Why?
|
Databases, Factual | 2 | 2020 | 353 | 0.070 |
Why?
|
Guanine | 1 | 2007 | 15 | 0.070 |
Why?
|
Inositol 1,4,5-Trisphosphate | 1 | 2006 | 6 | 0.070 |
Why?
|
Cobalt Radioisotopes | 1 | 2006 | 3 | 0.070 |
Why?
|
Pregnancy, Animal | 1 | 2006 | 19 | 0.070 |
Why?
|
Child, Preschool | 3 | 2020 | 1268 | 0.070 |
Why?
|
Weight Loss | 1 | 2010 | 480 | 0.070 |
Why?
|
Gestational Age | 4 | 2008 | 120 | 0.070 |
Why?
|
Karnofsky Performance Status | 2 | 2018 | 11 | 0.070 |
Why?
|
Receptors, Corticotropin | 1 | 2005 | 2 | 0.060 |
Why?
|
Adrenal Glands | 1 | 2005 | 4 | 0.060 |
Why?
|
Supratentorial Neoplasms | 1 | 2004 | 3 | 0.060 |
Why?
|
Swine | 2 | 2016 | 215 | 0.060 |
Why?
|
Fetal Development | 1 | 2004 | 26 | 0.060 |
Why?
|
Adenoviridae | 1 | 2004 | 66 | 0.060 |
Why?
|
Transforming Growth Factor alpha | 1 | 2003 | 4 | 0.060 |
Why?
|
DNA Methylation | 2 | 2015 | 140 | 0.060 |
Why?
|
Cause of Death | 2 | 2015 | 238 | 0.060 |
Why?
|
Pituitary Gland, Anterior | 1 | 2003 | 2 | 0.060 |
Why?
|
Hypothalamus | 1 | 2003 | 17 | 0.050 |
Why?
|
Sheep, Domestic | 1 | 2003 | 18 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 461 | 0.050 |
Why?
|
Renin-Angiotensin System | 1 | 2004 | 179 | 0.050 |
Why?
|
Mice | 2 | 2020 | 2485 | 0.050 |
Why?
|
Adrenocorticotropic Hormone | 3 | 2008 | 19 | 0.050 |
Why?
|
Equipment Design | 1 | 2003 | 171 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2017 | 463 | 0.050 |
Why?
|
Pregnancy | 4 | 2008 | 996 | 0.050 |
Why?
|
Intracranial Hemorrhages | 2 | 2013 | 33 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2003 | 294 | 0.050 |
Why?
|
Quality of Life | 3 | 2018 | 946 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 2 | 2016 | 743 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2016 | 1022 | 0.050 |
Why?
|
Cytotoxins | 1 | 2021 | 13 | 0.050 |
Why?
|
Dogs | 1 | 2021 | 120 | 0.050 |
Why?
|
Dyskinesias | 1 | 2020 | 3 | 0.050 |
Why?
|
Prevalence | 2 | 2014 | 981 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 115 | 0.040 |
Why?
|
Rats | 2 | 2016 | 1596 | 0.040 |
Why?
|
Photic Stimulation | 1 | 2020 | 158 | 0.040 |
Why?
|
Cell Movement | 1 | 2020 | 169 | 0.040 |
Why?
|
Receptors, Interleukin | 3 | 2003 | 16 | 0.040 |
Why?
|
Risk | 1 | 2020 | 320 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 875 | 0.040 |
Why?
|
United States | 2 | 2018 | 3938 | 0.040 |
Why?
|
Postoperative Period | 1 | 2018 | 97 | 0.040 |
Why?
|
Necrosis | 1 | 2018 | 53 | 0.040 |
Why?
|
Transcriptional Activation | 1 | 2018 | 42 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2018 | 73 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2020 | 766 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2018 | 122 | 0.040 |
Why?
|
Avoidance Learning | 1 | 2018 | 19 | 0.040 |
Why?
|
Neuronavigation | 1 | 2017 | 8 | 0.040 |
Why?
|
Parvovirinae | 1 | 2017 | 2 | 0.040 |
Why?
|
Hearing Tests | 1 | 2017 | 13 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 470 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2020 | 882 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2017 | 149 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 261 | 0.030 |
Why?
|
Blood Gas Analysis | 2 | 2008 | 17 | 0.030 |
Why?
|
Diffusion Tensor Imaging | 1 | 2016 | 29 | 0.030 |
Why?
|
Biopsy | 1 | 2017 | 259 | 0.030 |
Why?
|
Games, Experimental | 1 | 2015 | 4 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 163 | 0.030 |
Why?
|
DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2015 | 14 | 0.030 |
Why?
|
Electrodes, Implanted | 1 | 2015 | 41 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2008 | 833 | 0.030 |
Why?
|
Spinal Cord | 1 | 2016 | 130 | 0.030 |
Why?
|
Recovery of Function | 1 | 2016 | 199 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2015 | 71 | 0.030 |
Why?
|
Reoperation | 1 | 2015 | 227 | 0.030 |
Why?
|
Action Potentials | 1 | 2015 | 178 | 0.030 |
Why?
|
Levodopa | 1 | 2014 | 14 | 0.030 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2014 | 23 | 0.030 |
Why?
|
Influenza B virus | 1 | 2014 | 20 | 0.030 |
Why?
|
Dacarbazine | 1 | 2014 | 29 | 0.030 |
Why?
|
Brain Stem | 1 | 2014 | 20 | 0.030 |
Why?
|
Fetal Blood | 2 | 2005 | 38 | 0.030 |
Why?
|
Models, Animal | 1 | 2014 | 169 | 0.030 |
Why?
|
Receptors, Interleukin-13 | 2 | 2003 | 9 | 0.030 |
Why?
|
Interleukin-13 Receptor alpha1 Subunit | 2 | 2003 | 10 | 0.030 |
Why?
|
Hemorrhage | 1 | 2014 | 100 | 0.030 |
Why?
|
Models, Neurological | 1 | 2014 | 117 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2003 | 170 | 0.030 |
Why?
|
Pain | 1 | 2015 | 288 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 101 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 185 | 0.030 |
Why?
|
Beta Rhythm | 1 | 2012 | 1 | 0.030 |
Why?
|
Hypokinesia | 1 | 2012 | 3 | 0.030 |
Why?
|
Antiparkinson Agents | 1 | 2012 | 10 | 0.030 |
Why?
|
Embolization, Therapeutic | 1 | 2013 | 87 | 0.030 |
Why?
|
Receptors, Progesterone | 1 | 2012 | 72 | 0.030 |
Why?
|
Regression Analysis | 1 | 2013 | 293 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2005 | 508 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2012 | 113 | 0.030 |
Why?
|
Pilot Projects | 1 | 2014 | 543 | 0.030 |
Why?
|
Receptor, erbB-2 | 1 | 2012 | 65 | 0.030 |
Why?
|
Radiography | 1 | 2013 | 376 | 0.030 |
Why?
|
Electric Stimulation | 1 | 2012 | 104 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2012 | 40 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 109 | 0.030 |
Why?
|
Psychomotor Performance | 1 | 2012 | 99 | 0.030 |
Why?
|
Radiometry | 1 | 2012 | 40 | 0.030 |
Why?
|
Pain, Postoperative | 1 | 2014 | 179 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2014 | 762 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 371 | 0.020 |
Why?
|
Facial Paralysis | 1 | 2011 | 7 | 0.020 |
Why?
|
Hydrocephalus | 1 | 2011 | 12 | 0.020 |
Why?
|
Survivors | 1 | 2013 | 164 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2011 | 40 | 0.020 |
Why?
|
Otitis Media | 1 | 2011 | 23 | 0.020 |
Why?
|
Pons | 1 | 2010 | 6 | 0.020 |
Why?
|
Craniopharyngioma | 1 | 2010 | 8 | 0.020 |
Why?
|
Spinal Nerve Roots | 1 | 2010 | 14 | 0.020 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2010 | 41 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 35 | 0.020 |
Why?
|
Pituitary Neoplasms | 1 | 2010 | 17 | 0.020 |
Why?
|
Emaciation | 1 | 2010 | 4 | 0.020 |
Why?
|
Medical Records | 1 | 2010 | 76 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2011 | 148 | 0.020 |
Why?
|
Gastroesophageal Reflux | 1 | 2010 | 25 | 0.020 |
Why?
|
Essential Tremor | 1 | 2010 | 12 | 0.020 |
Why?
|
Endoscopy | 1 | 2010 | 58 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 297 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2009 | 80 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2008 | 66 | 0.020 |
Why?
|
Decompression, Surgical | 1 | 2009 | 55 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2008 | 78 | 0.020 |
Why?
|
Asthma | 1 | 2010 | 259 | 0.020 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2007 | 1 | 0.020 |
Why?
|
Radioactivity | 1 | 2006 | 2 | 0.020 |
Why?
|
Half-Life | 1 | 2006 | 23 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2007 | 100 | 0.020 |
Why?
|
Body Weight | 1 | 2008 | 310 | 0.020 |
Why?
|
Mental Disorders | 1 | 2008 | 121 | 0.020 |
Why?
|
Adrenal Cortex | 1 | 2005 | 3 | 0.020 |
Why?
|
Triiodothyronine | 1 | 2004 | 7 | 0.020 |
Why?
|
Logistic Models | 1 | 2007 | 781 | 0.020 |
Why?
|
Thyroxine | 1 | 2004 | 16 | 0.020 |
Why?
|
Denervation | 1 | 2004 | 13 | 0.020 |
Why?
|
Injections, Intralesional | 1 | 2004 | 15 | 0.020 |
Why?
|
Viral Vaccines | 1 | 2004 | 11 | 0.020 |
Why?
|
Adenovirus E1B Proteins | 1 | 2004 | 19 | 0.020 |
Why?
|
Receptors, Angiotensin | 1 | 2004 | 61 | 0.020 |
Why?
|
Virus Replication | 1 | 2004 | 42 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2004 | 69 | 0.020 |
Why?
|
Renin | 1 | 2004 | 109 | 0.010 |
Why?
|
Inhibitory Concentration 50 | 1 | 2003 | 22 | 0.010 |
Why?
|
Pseudomonas | 1 | 2003 | 6 | 0.010 |
Why?
|
Receptors, Interleukin-4 | 1 | 2003 | 6 | 0.010 |
Why?
|
Receptors, Transferrin | 1 | 2003 | 10 | 0.010 |
Why?
|
Microscopy, Confocal | 1 | 2003 | 65 | 0.010 |
Why?
|
Drug Synergism | 1 | 2003 | 66 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2003 | 58 | 0.010 |
Why?
|
Survival | 1 | 2003 | 13 | 0.010 |
Why?
|
Receptors, Corticotropin-Releasing Hormone | 1 | 2003 | 1 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 63 | 0.010 |
Why?
|
Receptors, Vasopressin | 1 | 2003 | 7 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2003 | 185 | 0.010 |
Why?
|
Absorbable Implants | 1 | 2003 | 24 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2003 | 104 | 0.010 |
Why?
|
Polymers | 1 | 2003 | 64 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 632 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2003 | 288 | 0.010 |
Why?
|
Seizures | 1 | 2003 | 64 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 301 | 0.010 |
Why?
|
Biocompatible Materials | 1 | 2003 | 232 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2003 | 495 | 0.010 |
Why?
|